MUSC researchers at the Hollings Cancer center are making strides in new developments for leukemia treatment.Sophie Paczesny, ...

Cancer patients who receive COVID boosters are far less likely to be hospitalized, but vaccination rates remain alarmingly ...

Panelists discuss how treatment selection between combination immunotherapy (IO) and chemotherapy alone should favor the FDA-approved carboplatin-paclitaxel-retifanlimab regimen for most patients with ...

While we have returned to many aspects of pre-pandemic life, the coronavirus has not completely disappeared.  Notably, cancer ...

Triple-negative breast cancer (TNBC) comprises 10–15% of all breast cancers. It is a very heterogeneous disease, ...

An expert discusses how emerging trial data, particularly from ASCENT-04, are reshaping first-line treatment strategies for ...

Bria-IMT plus a checkpoint inhibitor improved survival versus Trodelvy and chemo in patients with heavily pretreated ...

From diagnosis methods to management of comorbid infections, new lung cancer protocols adaptable for various conditions ...

The hunt for a medical breakthrough has been caught up in the Trump administration's political assault on the university.

Fact checked by Nick Blackmer Karen Peterson was diagnosed with stage 1 triple-negative breast cancer in 2015. After undergoing three months of chemotherapy with difficult side effects, she made the ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

The European Commission (EC) has approved BeOne Medicines’ Tevimbra (tislelizumab) as part of a first-line combination treatment for nasopharyngeal cancer.